Erastin2

Erastin2 is a ferroptosis inducer and an inhibitor of the system x_c^- cystine/glutamate transporter.^1,2 It inhibits glutamate release in CCF-STTG1 cells (IC₅₀ = 0.0035 µM).² It induces cell death in HAP1 cells when used at a concentration of 5 µM, an effect that can be blocked by the ferroptosis inhibitor ferrostatin-1 (Item No. 17729) or deferoxamine (Item No. 14595).¹ Erastin2 also induces ferroptotic cell death in HT-1080 cells (EC₅₀ = 0.15 µM), an effect that can be blocked by the reducing agent β-mercaptoethanol (EC₅₀ = >20 µM).³ It increases lipid peroxidation in HT-1080 cells when used at a concentration of 1 µM.

WARNING This product is not for human or veterinary use.

1. Cao, J.Y., Poddar, A., Magtanong, L., et al. A genome-wide haploid genetic screen identifies regulators of glutathione abundance and ferroptosis sensitivity. Cell Rep. 26(6), 1544-1556 (2019).

2. Dixon, S.J., Patel, D.N., Welsch, M., et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife 3, e02523 (2014).

3. Magtanong, L., Ko, P.-J., To, M., et al. Exogenous monounsaturated fatty acids promote a ferroptosis-resistant cell state. Cell Chem. Biol. 26(3), 420-432 (2019).

Li, Z., Ferguson, L., Deol, K.K., et al. Ribosome stalling during selenoprotein translation exposes a ferroptosis vulnerability. Nat. Chem. Biol. (2022).

Ubellacker, J.M., Tasdogan, A., Ramesh, V., et al. Lymph protects metastasizing melanoma cells from ferroptosis. Nature 585(7823), 113-118 (2020).